CURRICULUM VITAE Mark Richard Vesely, M.D. Associate Professor, Department of Medicine Division of Cardiovascular Medicine, Interventional Cardiology Section University of Maryland School of Medicine Date

Oct 1, 2016

Contact Information Business Address: Business Phone: Fax Number: Email: Education 1991-1994

1997-2001

110 South Paca Street, 7th Floor Baltimore, MD 21201 (410) 328-1044 (410) 328-7241 [email protected]

Bachelor of Science, Biochemistry Trinity College, Hartford, CT Doctor of Medicine George Washington University School of Medicine, Washington, DC

Post Graduate Education and Training 2001-2004 Internship and Residency: Internal Medicine Dept Internal Medicine, University of Maryland Medical Center, Baltimore, MD 2004-2007

Clinical Fellowship: Cardiovascular Disease Division of Cardiology, University of Maryland Medical Center, Baltimore, MD

2007-2008

Clinical Fellowship: Interventional Cardiology Division of Cardiology, University of Maryland Medical Center, Baltimore, MD

Certifications 2004 Diplomat, American Board of Internal Medicine 2007 Diplomat, ABIM, Cardiovascular Disease 2008 Diplomat, ABIM, Interventional Cardiology 2008 Diplomat, Certification Board of Nuclear Cardiology Medical Licensures 2008-present Maryland Board of Physicians Employment History Academic Appointments 2004-2008 Assistant Instructor of Medicine University of Maryland School of Medicine, Baltimore, MD (UMSOM)

Mark R. Vesely, M.D. Page 2 2008- 2016

Assistant Professor, Department of Medicine UMSOM

2016-present Associate Professor, Department of Medicine UMSOM Other Employment 1994- 1997 Research Technician Department of Cardiology/Division of Genetics Children's Hospital/Harvard Medical School, Boston, MA 1998 - 2000

Research Assistant Children’s Research Institute Children’s National Medical Center, Washington, DC

Professional Society Memberships 2008-present Fellow, American College of Cardiology 2008-present Fellow, Society for Cardiovascular Angiography & Interventions 2012-present Member, American Heart Association Honors and Awards 1994 Thomas H. Bissonnette Teaching Fellowship Trinity College, Hartford, CT 1994

Graduated with Honors in Biochemistry Trinity College, Hartford, CT

1998

3rd Place Poster, 63rd Annual William Beaumont Research Day George Washington University School of Medicine, Washington, DC

1998

Member, William Beaumont Honorary Research Society George Washington University School of Medicine, Washington, DC

1999

Tauber Scholar George Washington University School of Medicine, Washington, DC

2007

Nathan H. Carliner, M.D. Scholar Award Division of Cardiology, UMDSOM, Baltimore, MD

2013

2013 Super Doctors® Rising Stars Cardiology: Washington, DC – Baltimore – Northern Virginia region Limited to 2.5% of regional physicians

Mark R. Vesely, M.D. Page 3

Clinical Activities Clinical Expertise Invasive/Interventional Cardiology: Diagnostic cardiac catheterization Hemodynamics and Coronary Angiography Percutaneous Coronary Intervention Transcatheter Mitral Valve Repair Balloon Mitral Valvuloplasty Balloon Aortic Valvuloplasty Intra-aortic Balloon Pump Impella Ventricular Assist Device Nuclear Cardiology: myocardial perfusion stress testing Cardiovascular Disease: general consultative and inpatient management Echocardiography Scope of Clinical Practice 2008-present Attending Physician, Cardiac Catheterization Laboratory, UMMC & BVAMC Diagnostic and Interventional Cardiology Procedures Currently: 9 hours/day, 5 days/week, 39 weeks/year 2008-present General Cardiology Outpatient Practice University of MD Cardiology Physicians at Westminster, Westminster, MD Currently: 3 hours/day, 5 days/week, 13 weeks/year 2008-present Inpatient / Interventional Cardiology Services Carroll Hospital Center, Westminster, MD Currently: 6 hours/day, 5 days/week, 13 weeks/year 2008-present Interventional Cardiology Call Coverage: UMMC and Carroll Hospital Center Currently: 1-2 weeknights/week and 1-2 weekends/month, 52 weeks/year Innovative Techniques and Program Development 2013-present Multi-disciplinary Mitral Valve Program, University of Maryland Heart Center Only program in State of Maryland to offer commercially available Transcatheter Mitral Valve Repair with MitraClip® system Administrative Service Institutional Service 1999-2001 Medical Student Representative, Faculty Senate Research Advisory Committee George Washington University School of Medicine, Washington, DC 2006-2008

Fellow Representative, Cardiology Educational Task Force Division of Cardiology, UMDSOM, Baltimore, MD

Mark R. Vesely, M.D. Page 4

2008-2013

Associate Program Director, Interventional Cardiology Fellowship University of Maryland School of Medicine, Baltimore, MD

2009-2010

Member, Cardiology Educational Task Force Division of Cardiology, UMDSOM, Baltimore, MD

2010

Member, Physician Advisory Group Office of Referring Physicians, UMMC, Baltimore, MD

2010-2011

Director, Return to Sender Initiative Division of Cardiology, UMDSOM, Baltimore, MD

2012- 2014

Member, School of Medicine Council UMDSOM, Baltimore MD

2012-present Member, General Clinical Research Center Advisory Committee UMDSOM, Baltimore MD 2013–present Program Director, Interventional Cardiology Fellowship Program University of Maryland School of Medicine, Baltimore, MD 2013–present Medical Director Cardiac Catheterization Laboratory Baltimore Veterans Administration Medical Center 2013-present Co-Chair, Pharmacogenomics Subcommittee Pharmacy and Therapeutics Committee University of Maryland Medical Center 2013-present Member, Radiation Safety Committee Baltimore Veterans Administration Medical Center Local and National Service National Service 2012 Session Moderator, Hybrid Treatment of Coronary Artery Disease Surgical, Interventional, & Hybrid Procedures Symposium: Coronary Intervention Transcatheter Cardiovascular Therapeutics (TCT) conference, Miami FL 2013

Ad Hoc Reviewer, International Journal of Medical Sciences (1x/yr)

2013

Abstract Reviewer, Transcatheter Cardiovascular Therapeutics conference

2015

Ad Hoc Reviewer, Emergency Medicine Journal (1x/yr)

Mark R. Vesely, M.D. Page 5 2016

Ad Hoc Reviewer, Journal of the American College of Cardiology (1x/yr)

2015-present Member, Interventional Program Directors & Training Standards Committee Society of Coronary Angiography and Interventions 2015-present Member, Structural Heart Disease Committee Society of Coronary Angiography and Interventions 2015-present Member, Interventional Heart Failure Work Group Society of Coronary Angiography and Interventions Local Service 2010 Session Moderator, Integrated Cardiovascular Repair Workshop 2010 Baltimore, MD 2013

Informational TV interview: Heart disease: Prevention and Treatment Direct Connection with Jeff Salkin Maryland Public Television

Teaching Service Undergraduate Student Teaching 1992-1993 Teaching Assistant: Organic Chemistry Laboratory Department of Chemistry, Trinity College, Hartford, CT 1994

Teaching Associate: Cells, Metabolism, and Heredity Department of Biology, Trinity College, Hartford, CT

Medical Student Teaching 2000-2001 Mentor to First Year Medical Students, Teaching Interview & Physical Exam MSIV medical student elective: The Clinician as Medical Educator George Washington University School of Medicine, Washington, DC 2004-2008

Introduction to Clinical Medicine, UMSOM Small Group Teaching 10-15 hrs/year, 2-4 medical students/group

Resident and Fellow Teaching 2004 - 2008 Fellow, Inpatient CCU service University of Maryland Medical Center 2 months/year, 1-3 MS (MS III and MS IV), 4 Residents 2004-2008

Fellow, Cardiology Consult Service University of Maryland Medical Center 2 months/year, 1-3 MS (MS III and MS IV), 4 Residents

Mark R. Vesely, M.D. Page 6 2008 - present Attending Physician, Cardiac Catheterization Laboratory 2 Interventional Cardiology Fellows, 2-3 General Cardiology Fellows 9 hours/day, 5 days/week, 39 weeks/year Grant and Contract Support Active Grants: 07/01/16-06/30/17

(PI, 0%) Training Grant: Interventional Cardiology Fellowship Program. To fund educational materials and activities for current trainees. Industry sponsor: Medtronic Total Direct Costs: $22,000

Completed Grants: 09/01/10-08/31/2015 (Co-investigator, 10%) PI: A. Shuldiner “Translational Pharmacogenomics Project” NIH U01HL105198-06 Total Costs (Direct + Indirect; 5-year study): $13,557,37 Role: subject recruitment, Cardiology expertise 07/ 01/13-06/30/14

(PI, 0%) Training Grant to support Interventional Cardiology Fellowship Program. Funds dedicated for support of salary costs for current trainees. Industry sponsor: Boston Scientific Corporation

07/01/15-06/30/16

(PI, 0%) Training Grant: Interventional Cardiology Fellowship Program. Funds dedicated for support of salary costs for current trainees. Industry sponsor: Medtronic Total Direct Costs: $22,000

Active Contracts: 07/01/09-present

10/01/10-present

(Site-PI, 0%) “A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion following acute myocardial infarction” Industry sponsored multi-center trial: Osiris Therapeutics, Inc. Total Costs (Direct + Indirect): $413,462 (Co-investigator, 0%); PI: P. Reyes “ALERTS: AngelMed for Early Recognition and Treatment of STEMI” Industry sponsored multi-center trial: Angel Medical Systems Total Costs (Direct + Indirect): $136,197 Role: subject recruitment and follow up care

Mark R. Vesely, M.D. Page 7 04/01/12-present

(Site-PI, 0%) “PreSERVE-AMI Study: A Prospective randomized double blinded placebo controlled phase II trial of intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.” Industry sponsored multi-center trial: Amorcyte, Inc. Total Costs (Direct + Indirect): $372, 815

10/01/13-present

(Site Co-PI, 0%) “COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation” Industry sponsored multi-center trial: Evalve, Abbott Vascular Total Costs (Direct + Indirect): $157,000

Completed Contracts: 02/01/09-09/30/11 (Co-investigator, 0%); PI: P. Reyes “TRACER: Trial to Assess the Effects of SCH530348 in Preventing Heart Attack and Stroke in Patients with Acute Coronary Syndrome” Industry sponsored multi-center trial: Schering-Plough Total Direct Costs: $199, 550 Role: subject recruitment and follow up care

05/01/09-03/31/12

(Co-investigator, 0%); PI: P. Reyes “TIMI-50: Trial to Assess the Effects of SCH530348 in Preventing Heart Attack and Stroke in Patients with Atherosclerosis” Industry sponsored multi-center trial: Schering-Plough Total Direct Costs: $55, 933 Role: subject recruitment and follow up care

09/01/10-08/31/12

(Co-investigator, 0%); PI: J. Bonatti “Hybrid Revascularization Observational Study” NIH/NHLBI sponsored multi-center trial, sub-contract Total Direct Costs: $20,200 Role: subject recruitment and Interventional Cardiology expertise Total Direct Costs: $20,000

Publications

Peer Reviewed Journal Articles 1. Benson DW, MacRae CA, Vesely MR, Walsh EP, Seidman JG, Seidman CE, Satler CA Missense mutation in the pore region of HERG causes familial long QT syndrome. Circulation 1996; 93(10):1791-5.

Mark R. Vesely, M.D. Page 8 2.

3. 4.

5.

6.

7.

8.

9.

10. 11.

12.

13.

14.

15.

Satler CA, Walsh EP, Vesely MR, Plummer MH, Ginsburg GS, Jacob HJ. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome. Am J of Med Genet 1996; 65(1):27-35. Prigodich RV, Vesely MR. Characterization of the complex between bovine osteocalcin and type I collagen. Arch Biochem Biophys 1997; 345(2):339-41 Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long QT syndrome. Circulation 1998; 97(2):142-6 Satler CA, Vesely MR, Duggal P, Ginsburg GS, Beggs, AH. Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome. Human Genet 1998; 102(3): 265-72 Wattanasirichaigoon D, Vesely MR, Duggal P, Levine JC, Blume ED, Wolff GS, Edwards SB, Beggs AH. Sodium channel abnormalities are infrequent in patients with long QT syndrome: identification of two novel SCN5A mutations. Am J Med Genet. 1999 Oct 29;86(5):470-6. Mehra MR, Uber PA, Walther D, Vesely MR, Wohlgemuth JG, Prentice J, Tayama D, Billingham M. Gene Expression Profiles And B-Type Natriuretic Peptide Elevation In Heart Transplantation: More Than A Hemodynamic Marker. Circulation. 2006 Jul 4;114(1 Suppl):I21-6. Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, Marshall J, Cines M. A double-blind placebo controlled pilot study of controlled release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007 May;153(5):868 Vesely MR, Li S, Kop W, Reese A, Marshall J, Shorofsky SR, Gottlieb SS, Mehra MR, Gottdiener JG. Test-retest Reliability of Assessment for for Intraventricular Dyssynchrony By Tissue Doppler Echocardiography. Am J Cardiol. 2008 Mar 1;101(5): 645-650 Vesely MR, Dilsizian V. Nuclear Cardiac Stress Testing in the Era of Molecular Medicine. J Nucl Med. 2008 Mar; 49(3): 399-413 Schwartz DJ, Kop WJ, Park MH, Vesely MR, Li S, Mehra MR, Gottdiener JS. Evidence for early right ventricular and septal mechanical activation (Interventricular dyssynchrony) in pulmonary hypertension. Am J Cardiol. 2008 Nov1;102(9):1273-7 Rehman A, Garcia J, Deshpande S, Odonkor P, Reicher B, Vesely M, Zimrin D, Griffith B, Bonatti, J. Totally endoscopic coronary artery bypass grafting is feasible in morbidly obese patients. Heart Surg Forum. 2009 Jun;12(3):E134-6 Bonatti J, Lehr E, Vesely MR, Friedrich G, Bonaros N, Zimrin D. Hybrid coronary revascularization:which patients? When? How? Curr Opin Cardiol. 2010Nov;25(6):56874. Lehr EJ, Zimrin D, Vesely M, Odonkor P, Griffith B, Bonatti J. Axillary-coronary sequential vein graft for total endoscopic triple coronary artery bypass. Ann Thorac Surg. 2010 Nov;90(5):e79-81. Zimrin D, Bonatti J, Vesely MR, Lehr, EJ. Hybrid Coronary Revascularization: An Overview of Options for Anticoagulation and Platelet Inhibition. Heart Surg Forum. 2010 Dec 1; 13(6): E405-8

Mark R. Vesely, M.D. Page 9 16.

17. 18.

19.

20. 21.

22.

23.

24.

25.

26.

27.

28.

Beitelshees A, Horenstein R, Vesely M, Mehra M, Shuldiner AR. Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. Clin Pharmacol Ther. 2011 Mar; 89(3):455-9 Vesely MR, Dilsizian V. Microvascular Angina: Assessment of Coronary Blood Flow, Flow Reserve, and Metabolism. Curr Cardiol Rep. 2011 Apr;13(2):151-8 Bonatti J, Lehr EJ, Vesely M, Friedrich G, Schachner T, Bonaros N, Griffith B, Zimrin D. Hybrid Coronary Revascularization – Techniques and Outcome. European Surgery. 2011; 43(4) 198-204 Wiedemann D, Bonaros N, Schachner T, Weidinger F, Lehr EJ, Vesely M, Bonatti J. Surgical Problems and Complex Procedures: Issues for Operative Time in Robotic Totally Endoscopic Coronary Artery Bypass Grafting. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):639-47 Shuldiner AR, Vesely MR, Fisch A. CYP2C19 Genotype and Cardiovascular Events. JAMA. 2012 Apr; 307(14):1482 Vesely MR, Lee JD, Zimrin D, Bonatti J. Advanced Hybrid Coronary Revascularization (HCR) using Robotic Totally Endoscopic Triple Bypass Surgery and Left Main Percutaneous Intervention. J Thorac Cardiovasc Surg. 2012 Oct; 144(4):986-7 Bonatti J, Zimrin D, Lehr EJ, Vesely MR, Kon Z, Wehman B, DeBiasi A, Hofauer B, Weidinger F, Schachner T, Bonaros N, Friedrich G. Hybrid Coronary Revascularization Using Robotic Totally Endoscopic Surgery – Perioperative Outcome and 5-Year Results. Ann Thorac Surg. 2012 Dec (94):1920-6. PMID 23103003 Bonaros N, Schachner T, Lehr E, Kofler M, Wiedemann D, Hong P, Wheman B, Zimrin D, Vesely M, Friedrich G, Bonatti J. Five Hundred cases of Robotic Totally Endoscopic Coronary Artery Bypass Grafting: Predictors of Success and Safety. 2013 Mar;95:80312. PMID 23312792 Shuldiner AR, Relling MV, Peterson JF, Hicks JK, …, Vesely M, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013 Aug;94(2):207-10. PMID 23588301 Weidinger F, Schachner T, Bonaros N, Hofauer B, Lehr EJ, Vesely M, Zimrin D, Bonatti J. Predictors and consequences of postoperative atrial fibrillation following robotic totally endoscopic coronary bypass surgery. Eur J Cardiothorac Surg. 2014 Feb;45(2):318-22. PMID 23704711 Srivastava M, Vesely MR, Lee J, Lehr E, Wehman B, Bonaros N, Schachner T, Friedrich G, Zimrin D, Bonatti J. . Robotically-Assisted Hybrid Coronary Revascularization: Does Sequence of Intervention Matter? Innovations: Technology and Techniques in Cardiothoracic and vascular Surgery. 2013 May-Jun;8(3):177-83. PMID 23989810 Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, …, Vesely MR. Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet. 2014 Mar;166(1):76. PMID 24616408 Bonaros N, Schachner T, Kofler M, Lehr E, Lee J, Vesely M, Zimrin D, Feutchner G, Friedrich G, Bonatti J. Advanced hybrid closed chest revascularization: an innovative strategy for the treatment of multivessel coronary artery disease. Eur J Cardiothorac Surg. 2014 Dec;46(6):e94-102. PMID 25256825

Mark R. Vesely, M.D. Page 10 29.

Vesely MR, Benitez RM, Robinson SW, Collins JA, Dawood MY, Gammie JS. Surgical and Transcatheter Mitral Valve Repair for Severe Chronic Mitral Regurgitation: A review of clinical indications and patient assessment. J Am Heart Assoc. 2015 Dec 11;4(12): 1-8. PMID 26656862

30.

Puskas J, Halkos, M, DeRose JJ, Bagiella E, Miller M, Overbey J, Bonatti J, Vesely M, Sutter F, Lynch J, Kirkwood K, Shapiro T, Boudoulas K, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff S, Zhao D, Gelijns A, Szeto W, Weisz G, Argenziano M, Liberman H, Matthai W, Ascheim D. Hybrid Coronary Revascularization for the Treatment of Multi-vessel Coronary Artery Disease: A Multi-Center Observational Study. J Am Coll Cardiol. 2016 Jul 26;68(4): 356-65. PMID 27443431

Submitted or In-Revision Peer Reviewed Journal Articles 1. Watkins AC, Wehman B, Vesely MR, Griffith BP. The Effects of Combined Mesenchyma and Cardiac Stem Cell Therapy in a Porcine Model of Ischemic Cardiomyopathy: Early Findings. J Thorac Cardiovasc Surg. Submitted June 2015.

Non-Peer Reviewed Journal Articles 1. Vesely MR and Kelemen MD. Cardiac Risk Assessment: Matching Intensity of Therapy to Risk. In: Cardiology Clinics of North America. Cardiol Clin. 2006;24(1):67-78 2.

Mistry N, Vesely MR. Acute Coronary Syndromes: From ED to the CCU. Cardiol Clin. 2012 Nov; 30(4):617-27

Book Chapters 1. Vesely MR, Arrighi JA, Gurm GS, Kommana H, Dilsizian V. Post-MI Risk Stratification, in Multimodality Imaging in Cardiovascular Medicine. C.M. Kramer, Editor. 2010, Demos Medical: New York. p. 71-91 2. Srivastava M, Zimrin D, Taylor B, Vesely MR. Hybrid coronary revascularization: an overview of options for anticoagulation and platelet inhibition in Robotic Cardiac Surgery. C. Gao, Editor. 2013, Springer

Abstracts and/or Proceedings Poster Presentations 1998 A complete analysis of the HERG gene coding sequence for LQTS-associated mutations 63rd Annual William Beaumont Research Day, Washington, DC 2002 Clinical Vignette: Sarcoidosis in an 80 year old male Chapter Scientific Meeting, Maryland Chapter, ACP-ASIM, Baltimore, MD 2010 Pollock J, Perrin P, Lakin C, Grant M, Vesely M, Poston R, Zimrin D. Five-Year Mortality for Hybrid Coronary Revascularization versus CABG Integrated Cardiovascular Repair Workshop 2010, Baltimore, MD

Mark R. Vesely, M.D. Page 11 2010

2013

2013

Lehr EJ, Bonaros N, Schachner T, Wiedemann D, Weidinger F, Vesely M, Zimrin D, Griffith B, Bonatti J. Hybrid treatment of multivessel coronary artery disease using robotic surgical techniques. Canadian Cardiovascular Conference 2010. Montreal, Canada Vesely MR, Lehr EJ, Bonaros N, Schachner T, Friedrich G, Kofler M, Srivastava M, Zimrin D, Bonatti J. Predictors of Long Term Outcomes in Hybrid Coronary Revascularization. College of Cardiology Scientific Sessions, San Francisco,CA DeRose JJ, Liberman H, Matthai W, Szeto W, Parides M, Srinivas V, Bonatti J, Overbey J, Vesely M, Sutter F, Williams P, Shapiro T, Crestanello J, Boudoulas K, Smith P, Gehrig T, Ailawadi G, Davidson M, Zhao D, Argenziano M, Williams M, Puskas J, Halkos M, Ascheim D. Interventional Cardiologists and Cardiac Surgeons: Concordance Regarding Anatomic Eligibility for Hybrid Coronary Revascularization in >6,500 Patients. American College of Cardiology Scientific Sessions, San Francisco CA

Oral Presentations 1997 Complete analysis of the HERG gene for mutations in long QT syndrome American Heart Association, 68th Scientific Sessions, Orlando, FL 2003 Hypothermia inhibits Fas-mediated apoptosis in lung epithelial cells Chapter Scientific Meeting, Maryland Chapter, ACP-ASIM, Baltimore, MD 2004 Management of End-Stage Heart Failure. Senior Resident Talk Department of Internal Medicine, UMMS, Baltimore, MD 2013 Puskas JD, Ascheim D, Halkos M, Bagiella E, DeRose J, Miller M, Kirkwood K, Bonatti J, Srinivas V, Vesely M, Sutter F, Lynch J, Shapiro T, Boudoulas K, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff S, Zhao D, Gelijns A, Szeto W, Weisz G, Argenziano M, Matthai W. Hybrid Coronary Revascularization for the Treatment of Coronary Artery Disease: A Multicenter Observational Study. American College of Cardiology Scientific Sessions, San Francisca CA Major Invited Talks Local 1. Hybrid Coronary Revascularization: A Model for Interdisciplinary Treatment of Coronary Artery Disease Robotic Cardiovascular Revascularization Symposium Hatton Institute, Good Samaritan Hospital, Cincinnati OH, 2009 2. Intravenous Human Mesenchymal Stem Cells Following Acute Myocardial Infarction Maryland Stem Cell Research Symposium, Gaithersburg, MD, 2010 3. Stem Cell Therapies for Ischemic Heart Disease Medicine Grand Rounds, University of Maryland School of Medicine, 2011 4. Translational Pharmacogenetics Project: Logistics of Personalized Dual Anti-Platelet Therapy, CYP2C19 based Variability of Clopidogrel Activation Cardiology Grand Rounds, University of Maryland School of Medicine, Baltimore MD, 2013 5. Transcutaneous Approaches for Treatment of Mitral Regurgitation. 2015 Kyle Y. Swisher Day of Cardiology. St. Agnes Hospital. Baltimore MD. November, 2015

Mark R. Vesely, M.D. Page 12 National 6. Hybrid Coronary Revascularization - The Interventionalist Perspective American College of Cardiology Scientific Sessions, Atlanta GA, 2010 7. Case Presentation: Robotic Hybrid CABG/PCI Case American Association of Thoracic Surgery, Philadelphia PA, 2011 8. Hybrid Coronary Revascularization: An Interventional Cardiologist Perspective Society of Thoracic Surgeons 48th Annual Meeting, Fort Lauderdale FL, 2012 9. Hybrid Coronary Revascularization: The University of Maryland Experience Transcatheter Cardiovascular Therapeutics (TCT) conference, Miami FL, 2012 10. Pharmacogenetic Derived Personalization of Dual Anti-Platelet Therapy: CYP2C19 Based Variability of Clopidogrel Activation. AVA Heart Symposium. Veterans Administration MC, Washington DC, 2013